Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: A multicenter controlled study

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 3, 2004, Pages 369-374

  Xie, Yao ^a   Xu, Dao Zhen ^a   Lu, Zhi Meng ^b   Luo, Kang Xian ^c   Jia, Ji Dong ^d   Wang, Yu Ming ^e   Zhao, Gui Zhen ^f   Zhang, Shu Lin ^g   Zhang, Da Zhi ^h  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c FIRST MILITARY MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f CHINA MEDICAL UNIVERSITY   (China)

^g XI'AN JIAOTONG UNIVERSITY   (China)

^h CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis C; Genotype; Hepatitis C virus; Interferon; PEG IFN

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 4444271712     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmishi F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399.
2. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
3. Anne G, Martinot M, Boyer N, Auperin A, Breton VL, Degott C, et al. Quantitation of hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. J Hepatol 2001; 35: 399-405.
4. Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M, et al. Different genotype hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994;43:291-296.
5. Qu D, Li JS, Vitvitski L, Mechai S, Berby F, Tong SP, et al. Hepatitis C virus genotype in France: comparison of clinical features of patients infected with HCV type I and type II. J Hepatol 1994;21:70-75.
6. Zein NN, Poterucha JJ, Gross JB Jr, Wiesner RH, Therneau TM, Gossard AA, et al. Increases risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol 1996;91:2560-2562.
7. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002;36:S114-120.
8. McHutchison JG, Manns MP, Ling MH, Koury K, Albrecht JK. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factors for sustained virologic response when ribavirin dose is expressed as mg/kg of body weight? Hepatology 2001;34:329A.
9. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 779-787.
10. Medina J, Garcia-Buey L, Moreno-Monteagudo JA, Trapero-Marugan M, Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003; 60: 135-143.
11. Fukutomi T, Fukutomi M, Iwao M, Watanabe H, Tanabe Y, Hiroshige K, et al. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C. Med Sci Monit 2000;6:692-698.
12. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22: 1050-1056.
13. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994;21:12-17.
14. Tsubota A, Chayama K, Ikeda Y, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1104.
15. Kondo M, Tanaka K, Ikeda M, Arata S, Saiton S, Sakaguchi T, et al. Hepatic HCV RNA as a predictor of outcome after interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996;11:236-240.
16. Hino K, Sainokami S, Shimoda K, Lino S, Wamg Y, Okamoto H, et al. Genotype and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
17. Moreno L, Quereda C, Moreno A, Perez-Elias MJ, Antela A, Casado JL, et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients AIDS 2004;18:67-73.
18. Perez-Olmeda M, Soriano V, Asensi V, Morales D, Romero M, Ochoa A, et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003;19:1083-1089.
19. Jiao J, Wang JB. Effects of HCV genotypes and HLA-DRB alleles on the response of chronic hepatitis C patients to interferon alpha and libavilin. Zhonghua Gan Zang Bing Za Zhi 2003;11: 620-622.
20. Orito E. HCV genotype as a predictor of response to interferon therapy in patients with chronic hepatitis C. Nippon Rinsho 2001;59:1356-1362.
21. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-110.
22. Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, Saitoh S, et al. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology 2000;32:1138-1144.
23. McKennie VM, Mills PR, McCruden EA. The NS5A gene of hepatitis C in patients treated with IFN-alpha. J Med Virol 2000;60:367-378.
24. Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology 2000;32:889-896.
25. Nousbaum J, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers RL Jr, et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000;74:9028-9038.
26. Sun NX, Fan XF, Du SC. The study on hepatitis C genotype based on simmonds' classification by using restriction endonuclease method. Jiangshu Med 1999;25:481-483.
27. Karino Y, Toyota J, Sugawara M, Miyazaki K, Kuwata Y, Yamazaki K, et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003;18:404-410.
28. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.
29. Thelu MA, Baud M, Leroy V, Seigneurin JM, Zarski JP. Dynamics of viral quasispecies during interferon therapy in non responder chronic hepatitis C patients. J Clin Virol 2001;22:125-131.
30. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004;53:15-18.
31. Halfon P, Neumann AU, Bourliere M, Rieu A, Chadapaud S, Khiri H, et al. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat 2003;10:351-353.
32. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Eng J Med 1998;339:1493-1499.
33. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26:122S-127S.
34. Tassopoulos NC, Ketikoglou I, Tsantoulas D, Raptopoulou M, Hatzis G, Vafiadis I, et al. A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naive patients with chronic hepatitis C. J Viral Hepat 2003;10:383-389.
35. Mangia A, Minerva N, Annese M, Leandro G, Villani MR, Santoro R, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001;33:989-993.
36. Westin J, Lindh M, Nenonen N, Lagging LM, Norkrans G, Wejstal R. Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response. Scand J Infect Dis 2001; 33:110-115.
37. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-1083.
38. Portal I, Bourliere M, Halfon P, De Ledinghen V, Couzigou P, Bernard PH, et al. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patient: a prospective multicenter randomized controlled study. J Virol Hepatol 2003; 10: 215-223.
39. Sievert W. Management issues in chronic viral hepatitis: hepatitis C. J Gastroenterol Hepatol 2002;17:415-422.
40. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001;8:48-62.
41. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231-240.
42. Par A, Telegdy L, Gogl A, Muller E. Interferon therapy of chronic viral hepatitis in Hungary: 5-year experience. A multicenter study. Orv Hetil 1999 30;140:1227-1233.
43. O'Brien CB, Henzel BS, Moonka DK, Inverso J, Rook A. Extracorporeal photopheresis alone and with interferon-alpha2a in chronic hepatitis C patients who failed previous interferon therapy. Dig Dis Sci 1999;44:1020-1026.
44. Bellobuono A, Mondazzi L, Tempini S, Silini E, Ideo G. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment. Eur J Gastroenterol Hepatol 1997;9:1169-1177.
45. Saracco G, Olivero A, Ciancio A, Carenzi S, Smedile A, Cariti G, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002;36:959-966.
46. Saracco G, Olivero A, Ciancio A, Carenzi S, Rizzetto M. Therapy of chronic hepatitis C: a critical review. Curr Drug Targets Infect Disord 2003;3:25-32.